All Penny Stocks.com News: MabVax Therapeutics Commences Phase I Trial of HuMab-5B1

Mississauga, ON -- (SBWIRE) -- 03/21/2016 -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled "MabVax Therapeutics Commences Phase I Trial of HuMab-5B1."

Companies mentioned in this article include iShares NASDAQ Biotechnology (ETF) (NASDAQ:IBB) and MabVax Therapeutics Holdings Inc. (OTCQB:MBVX).

Article Excerpt:

After seeing a huge sell-off at the start of this year, the biotechnology sector is showing signs of a recovery. As sentiment on risk assets has improved in recent weeks, the biotech sector has once again found favor among investors.

The iShares NASDAQ Biotechnology (ETF) (NASDAQ:IBB) is up sharply in trading today. At last check, the ETF was up 2.38% to $257.32. While the ETF is still down almost 25% for the year, it has cut back some of its losses since the start of this month. In fact, for the month of March, the IBB is up 1.16%.

One Company making waves in the biotech sector today is MabVax Therapeutics Holdings Inc. (OTCQB:MBVX). Based in San Diego, California, MBVX is a clinical-stage oncology drug development company. The company is currently focusing on the development of vaccine and antibody-based products and vaccines to address unmet medical needs in the treatment of cancer.

The full version of this article can be found at:
http://www.allpennystocks.com/aps_us/special-reports/624/mabvax-therapeutics-commences-phase-i-trial-of-humab-5b1.htm

About AllPennyStocks.com
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.

AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.

Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.

Contact:

AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: (905) 361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com

Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.

For more information on this press release visit: http://www.sbwire.com/press-releases/all-penny-stockscom-news-mabvax-therapeutics-commences-phase-i-trial-of-humab-5b1-674655.htm

Media Relations Contact

Peter Szafranski
Telephone: 905-361-5680
Email: Click to Email Peter Szafranski
Web: http://www.allpennystocks.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X